Cargando…

Metformin: A New Inhibitor of the Wnt Signaling Pathway in Cancer

The biguanide drug metformin is widely used in type 2 diabetes mellitus therapy, due to its ability to decrease serum glucose levels, mainly by reducing hepatic gluconeogenesis and glycogenolysis. A considerable number of studies have shown that metformin, besides its antidiabetic action, can improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Conza, Domenico, Mirra, Paola, Fiory, Francesca, Insabato, Luigi, Nicolò, Antonella, Beguinot, Francesco, Ulianich, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486775/
https://www.ncbi.nlm.nih.gov/pubmed/37681914
http://dx.doi.org/10.3390/cells12172182
_version_ 1785103087037317120
author Conza, Domenico
Mirra, Paola
Fiory, Francesca
Insabato, Luigi
Nicolò, Antonella
Beguinot, Francesco
Ulianich, Luca
author_facet Conza, Domenico
Mirra, Paola
Fiory, Francesca
Insabato, Luigi
Nicolò, Antonella
Beguinot, Francesco
Ulianich, Luca
author_sort Conza, Domenico
collection PubMed
description The biguanide drug metformin is widely used in type 2 diabetes mellitus therapy, due to its ability to decrease serum glucose levels, mainly by reducing hepatic gluconeogenesis and glycogenolysis. A considerable number of studies have shown that metformin, besides its antidiabetic action, can improve other disease states, such as polycystic ovary disease, acute kidney injury, neurological disorders, cognitive impairment and renal damage. In addition, metformin is well known to suppress the growth and progression of different types of cancer cells both in vitro and in vivo. Accordingly, several epidemiological studies suggest that metformin is capable of lowering cancer risk and reducing the rate of cancer deaths among diabetic patients. The antitumoral effects of metformin have been proposed to be mainly mediated by the activation of the AMP-activated protein kinase (AMPK). However, a number of signaling pathways, both dependent and independent of AMPK activation, have been reported to be involved in metformin antitumoral action. Among these, the Wingless and Int signaling pathway have recently been included. Here, we will focus our attention on the main molecular mechanisms involved.
format Online
Article
Text
id pubmed-10486775
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104867752023-09-09 Metformin: A New Inhibitor of the Wnt Signaling Pathway in Cancer Conza, Domenico Mirra, Paola Fiory, Francesca Insabato, Luigi Nicolò, Antonella Beguinot, Francesco Ulianich, Luca Cells Perspective The biguanide drug metformin is widely used in type 2 diabetes mellitus therapy, due to its ability to decrease serum glucose levels, mainly by reducing hepatic gluconeogenesis and glycogenolysis. A considerable number of studies have shown that metformin, besides its antidiabetic action, can improve other disease states, such as polycystic ovary disease, acute kidney injury, neurological disorders, cognitive impairment and renal damage. In addition, metformin is well known to suppress the growth and progression of different types of cancer cells both in vitro and in vivo. Accordingly, several epidemiological studies suggest that metformin is capable of lowering cancer risk and reducing the rate of cancer deaths among diabetic patients. The antitumoral effects of metformin have been proposed to be mainly mediated by the activation of the AMP-activated protein kinase (AMPK). However, a number of signaling pathways, both dependent and independent of AMPK activation, have been reported to be involved in metformin antitumoral action. Among these, the Wingless and Int signaling pathway have recently been included. Here, we will focus our attention on the main molecular mechanisms involved. MDPI 2023-08-30 /pmc/articles/PMC10486775/ /pubmed/37681914 http://dx.doi.org/10.3390/cells12172182 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Conza, Domenico
Mirra, Paola
Fiory, Francesca
Insabato, Luigi
Nicolò, Antonella
Beguinot, Francesco
Ulianich, Luca
Metformin: A New Inhibitor of the Wnt Signaling Pathway in Cancer
title Metformin: A New Inhibitor of the Wnt Signaling Pathway in Cancer
title_full Metformin: A New Inhibitor of the Wnt Signaling Pathway in Cancer
title_fullStr Metformin: A New Inhibitor of the Wnt Signaling Pathway in Cancer
title_full_unstemmed Metformin: A New Inhibitor of the Wnt Signaling Pathway in Cancer
title_short Metformin: A New Inhibitor of the Wnt Signaling Pathway in Cancer
title_sort metformin: a new inhibitor of the wnt signaling pathway in cancer
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486775/
https://www.ncbi.nlm.nih.gov/pubmed/37681914
http://dx.doi.org/10.3390/cells12172182
work_keys_str_mv AT conzadomenico metforminanewinhibitorofthewntsignalingpathwayincancer
AT mirrapaola metforminanewinhibitorofthewntsignalingpathwayincancer
AT fioryfrancesca metforminanewinhibitorofthewntsignalingpathwayincancer
AT insabatoluigi metforminanewinhibitorofthewntsignalingpathwayincancer
AT nicoloantonella metforminanewinhibitorofthewntsignalingpathwayincancer
AT beguinotfrancesco metforminanewinhibitorofthewntsignalingpathwayincancer
AT ulianichluca metforminanewinhibitorofthewntsignalingpathwayincancer